Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case‒control study-Reference-Cited by-同舟云学术

Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case‒control study

Published:2020-03-22 Issue:6 Volume:189 Page:1182-1191
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Velzen Alice S.¹,Eckhardt Corien L.¹,Peters Marjolein¹,Oldenburg Johannes²,Cnossen Marjon³,Liesner Ri⁴,Morfini Massimo⁵,Castaman Giancarlo⁶,McRae Simon⁷,Bom Johanna G.⁸,Fijnvandraat Karin¹,

Affiliation:

1. Department of Pediatric Hematology, Immunology and Infectious Diseases Emma Children’s Hospital Academic Medical Center Amsterdam the Netherlands

2. Institute of Experimental Haematology and Transfusion Medicine University Clinic Bonn Bonn Germany

3. Department of Pediatric Oncology and Hematology Erasmus Medical Center Rotterdam the Netherlands

4. Department of Haematology & Oncology and Children's Haemophilia Comprehensive Care Centre Great Ormond Street Children's Hospital & Institute of Child Health London UK

5. Italian Association of Haemophilia Centres (AICE) Florence Italy

6. Department of Oncology Center for Bleeding Disorders Careggi University Hospital Firenze Italy

7. Department of Haematology Royal Adelaide Hospital Adelaide Australia

8. Sanquin Research and Department of Clinical Epidemiology Center for Clinical Transfusion Research Leiden University Medical Center Leiden the Netherlands

Funder

The Netherlands Organisation for Health, Research and Development

CSL

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16490

Reference36 articles.

1. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A

2. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A

3. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A

4. Australasian Paediatric Endocrine Group(2012).Australian Bureau of Statistics [Internet]. [cited 2015 Jan 21]. Available from:http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/4841.0Chapter22011

5. Australian Bureau of Statistics(2012).Centraal Bureau voor de Statistiek [Internet]. [cited 2015 Jan 21]. Available from:http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/4841.0Chapter22011

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII;Clinical and Applied Thrombosis/Hemostasis;2023-01

2. The Impact of Recombinant Versus Plasma-Derived Factor VIII Concentrates on Inhibitor Development in Previously Untreated Patients With Hemophilia A: A 2021 Update of a Systematic Review and Meta-Analysis;Cureus;2022-06-16

3. Nonsevere hemophilia A: often overlooked, but not forgotten;Current Opinion in Hematology;2020-07-21